Akin Gump Advises Galapagos on $185 Million Biotech Sale

Akin Gump has advised Galapagos N.V., the Euronext-listed biotech group, on the sale of its BioFocus and Argenta services divisions to Charles River Laboratories for $185 million. The transaction closed on April 1, 2014.

Formerly listed on AIM, Galapagos sold the shares and assets of its U.K.- and Netherlands-based services divisions to New York Stock Exchange listed Charles River Laboratories, one of the leading global life science service providers.

Galapagos views this as a transformational deal, as it looks to move away from biotech services and focus exclusively on its research and development program, developing innovative drugs for as-yet-unmet medical needs.

The Akin Gump team advising Galapagos was led by London corporate partner Harry Keegan, supported by Washington, D.C. corporate partner Tony Renzi and a team of London associates.

Founded in 1945, Akin Gump Strauss Hauer & Feld LLP is a leading international law firm with more than 850 attorneys in offices throughout the United States, Europe, Asia and the Middle East.